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ABSTRACT 
 
Background: Stanniocalcin-1 (STC-1) is a nerve cell-enriched protein involved 
in intracellular calcium homeostasis regulation. Its expression increases in 
response to ischemic stroke but whether it is altered in neurodegeneration is 
unknown. The main objective of this study was to examine if STC-1 is 
measureable in human cerebrospinal fluid (CSF) and whether the concentration 
of STC-1 is increased in CSF of patients with Alzheimer’s disease (AD) and 
other dementias, as compared to cognitively normal controls (CNC).  
 
Method: A total of 163 individuals from 2 centers in Sweden and France were 
included. Cohort A consisted of 40 patients who had CSF AD biomarker patterns 
indicative of or excluding AD (20 patients in each group). Cohort B consisted of 
43 patients, 11 of whom had AD with dementia, 12 of whom had prodromal AD, 
and 23 of whom had diagnoses of dementias other than AD. Cohort C included 
80 patients, 32 of whom had AD, 13 stable mild cognitive impairment (MCI) and 
15 with other diagnoses of dementia. Additionally, cohort C included 20 CNC. 
 
Results: CSF STC-1 concentration was readily measureable in all CSF samples 
and significantly increased in neurochemical AD patients vs. neurochemically 
normal controls (P<0.0001). In cohort B, STC-1 was higher in AD vs. prodromal 
AD, and other dementias, but the difference was not significant when correcting 
for multiple group comparisons. In cohort C, there was no significant difference 
in CSF STC-1 concentration between AD and CNC, however, STC-1 was 
increased in mAD and sMCI group. STC-1 concentration was significantly lower 
in patients with other dementias compared to AD and CNC. 
 
Conclusion: There was no consistent pattern of changes in CSF STC-1 between 
AD and control groups in three cross-sectional studies. However, consistently 
CSF STC-1 concentration was lower in patients with dementia diagnoses other 
than AD, both when comparing against AD patients and controls. 
 
INTRODUCTION 
 
Alzheimer’s disease (AD) is the most common cause of dementia in the elderly 1-
4. The main histopathological hallmarks of AD are intracellular neurofibrillary 
tangles and extracellular amyloid plaques. The tangles are mainly composed of 
phosphorylated tau, while the plaques contain amyloid β (Aβ).5,6 The 
histopathological changes in AD are reflected in cerebrospinal fluid (CSF) as 
reduced levels of the 42 amino acid isoform of A (Aβ1-42), and increased level 
of total tau (T-tau) and phosphorylated tau (P-tau). However, as other aspects of 
the disease are being unraveled, CSF markers that reflect other disease 
mechanisms (e.g. neuronal and synaptic injury) are gaining interest as potential 
diagnostic and prognostic markers.7,8 Such markers may provide insight into the 
different mechanisms implicated in AD pathogenesis and assist in identifying 
novel targets for therapies in the future. 
 
Stanniocalcin-1 (STC-1) is a 56-kDa homodimeric glycoprotein secreted 
hormone that was originally identified in bony fish, where it is believed to 
regulate calcium/phosphate homeostasis and protects against toxic 
hypercalcemia.9 STC-1 is expressed in various organs including neural cells, 
mature adipocytes, and megakaryocytes.10,11 High expression of STC-1 has been 
reported in terminally differentiated mammalian brain neurons, with the Purkinje 
cells, the large neurons of basal ganglia, and the pyramidal neurons in the 
neocortex being particularly rich in STC-1.12 STC-1 in brain neurons plays an 
important role against hypercalcemic and hypoxic damage.13 An upregulated 
neuronal expression of STC-1 has been reported in penumbra areas in human and 
rat brain infarction.13 
 
With the above in mind, we hypothesized that STC-1 would be altered in CSF of 
patients with AD.  We specifically tested the following hypotheses: i) STC-1 is 
secreted from neurons, ii) that STC-1 would be possible to measure in human 
CSF, and iii) STC-1 levels in CSF of patients with AD would be elevated. We 
therefore measured STC-1 in CSF from three independently recruited cohorts, 
including patients with AD and other types of dementias, as well as cognitively 
normal controls (CNC). 
 
METHODS 
 
Participants 
 
Cohort A 
Cohort A was our first explorative analysis cohort, collected at the Clinical 
Neurochemistry Laboratory at Sahlgrenska University Hospital. The CSF 
samples were from patients who sought medical advice because of cognitive 
impairment. Patients were designated as normal (n=20) or AD (n=20) according 
to CSF AD biomarker concentrations using cutoffs that are around 90% specific 
for AD14: total tau (T-tau) >350 ng/L and A42 <530 ng/L. None of the 
biochemically normal subjects fulfilled these criteria.  
 
Cohort B  
We also included an independent cohort, enrolled at xxx site in Paris, France, 
consisting of a total of 43 patients (12 AD cases, 12 prodromal AD, and 19 with 
other dementias (OD). The OD group consisted of patients with frontotemporal 
dementia (FTD) (n=9), non-AD dementia (NAAD) (n=5), and 5 with clinically 
undetermined cognitive disorder (UCD). 
 
Cohort C 
Cohort C included a total of 80 patients: 18 AD patients, 8 patients with mixed 
AD and cerebrovascular disease (mAD), 13 patients with stable mild cognitive 
impairment (sMCI) patients, 6 prodromal AD patients, 20 CNC and 15 patients 
with other dementias. The other dementia group consisted of patients with 
vascular dementia (VaD) (n = 13), dementia of Lewy body type (DLB) (n = 4), 
and FTD (n =1). The study participants were recruited at the memory clinic in 
Falköping, Sweden, and have been described in detail elsewhere.15 The CNCs 
were mostly spouses of the included patients but some were recruited by 
advertisements in local newspapers. These individuals had no subjective 
symptoms of cognitive dysfunction and were cognitively normal upon formal 
testing.  
 
 
 
Ethics 
 
The Institutional Review Board for medical research at the University of 
Gothenburg, Sweden, and XXX, Paris, France approved the use of human 
subjects for these studies. Written informed consent was obtained from all 
participants or, if incapable, from their next of kin, prior to the inclusion in the 
study.  
 
Biochemical procedure 
 
CSF was collected in polypropylene tubes by lumbar puncture through the L3-4 
or L4-5 interspace. All CSF samples were stored at −80 °C pending analysis. 
CSF concentrations of Aβ1-42, T-tau, and P-tau were measured with 
INNOTEST (Fujirebio, Ghent, Belgium). CSF concentrations of STC-1 were 
measured using single determinations, in a sandwich enzyme immunoassay, 
BioAssay™ ELISA Kit (Human), according to the instructions from the 
manufacturer and using two-fold dilution of the samples. All measurements were 
performed by board-certified laboratory technicians who were blinded to clinical 
data.   
 
APOE allele 
Genotyping for APOE (gene map locus 19q13.2) was performed using allelic 
discrimination technology (TaqMan; Applied Biosystems) or equivalent 
techniques. Genotypes were obtained for the 2 single-nucleotide polymorphisms 
that are used to define the ε2, ε3, and ε4 alleles unambiguously (rs7412 and 
rs429358). 
 
Statistical analyses 
We evaluated association between demographic factors, CSF STC-1, CSF AD 
biomarkers and mini-mental state examination (MMSE) score using Pearson’s 
correlation. For the group differences in sex, we used Pearson’s χ2 test.  Mann-
Whitney U test was used for pairwise comparison and for multiple group 
comparison Kruskal-Wallis test was used. Bonferroni correction was performed 
for all multiple comparisons. All tests were two-sided and statistical significance 
was determined at P<0.05. All statistical analyses were performed using R (v. 
3.0.3, The R Foundation for Statistical Computing). 
 
RESULTS 
 
Demographic characteristics of the study cohorts 
The sample size and demographic characteristics of all the three cohorts are 
summarized in Table 1. As expected, APOE ε4 prevalence was highest in 
patients with AD, and lowest in CNC, whereas MMSE score was lowest in 
patients with AD. Also, in all three cohorts, the levels of A1-42 were lower in 
AD patients, while the levels of T-tau and P-tau were significantly higher in AD 
(Table 1). The CSF STC-1 levels did not differ by age or sex in this cohort 
(Results in the Supplement). 
 
STC-1 was readily measureable in human CSF. The detection range for the assay 
was 31.2-2000 pg/mL, and all the samples were almost 10-fold higher than the 
lowest detection range. The concentrations of the samples were in mid region of 
the calibration curve. The CV of the calibration curve was less than 13 %.  
 
Increased STC-1 in neurochemically diagnosed AD cases  
CSF STC-1 concentration was significantly (P< 0.0001) increased in AD patients 
compared with CNC in cohort A (Figure 1A).  
 
Decreased STC-1 in other dementias versus AD and CNC 
In cohort B, the levels of CSF STC-1 were increased in AD patients vs. 
prodromal AD and patients with other dementias, however, the increase was not 
statistically significant (P=0.30 and P=0.77, respectively), when corrected for 
multiple group comparisons (Figure 1B). In cohort C, there was no significant 
difference in the levels of STC-1 between AD and CNC (Figure 1C). However, 
the levels of STC-1 were increased in mAD and sMCI compared with CNC?. 
The levels of STC-1 were significantly lower in other dementias vs. CNC and 
sMCI (P=0.02 and P=0.04, respectively), after correcting for multiple group 
comparisons (Figure 1C). When all the three cohorts were combined, the levels 
of STC-1 were significantly (P=0.004) elevated in AD vs. other dementias after 
correcting for multiple group comparison. Detailed analysis of CSF STC-1 
concentration among dementias other than AD, revealed significantly lower 
concentrations of CSF STC-1 in DLB and VaD patients (Figure 2A-B). 
 
Correlation of CSF STC-1 with markers of AD 
The CSF STC-1 levels correlated positively with T-tau (r=0.56, P<0.001) and P-
tau (r=0.51, P<0.001) in cohort A, while there was a negative correlation with 
Aβ1-42 (r= -0.30, P=0.06) (Figure 3). In cohort B, there was a positive 
correlation between STC-1 and T-tau, as well as P-tau (Figure 3). However, there 
was no significant correlation between STC-1 and T-tau in cohort C, while, there 
was a significant correlation with Aβ1-42 and P-tau (Figure 3).  
 
Stanniocalcin-1 levels and cognitive decline 
There was no correlation between the levels of STC-1 and MMSE score in 
cohort B (Figure 4). However, in cohort C the levels of STC-1 correlated with 
MMSE score (Figure 4). There was no significant correlation between STC-1 
and MMSE scores when both cohort B and C were combined (Figure 4).  
 
The effect of APOE ε4 on CSF STC-1 concentration  
In cohort C (the only cohort in which we had access to APOE genotype data), 
there was a significant association of APOE genotype and CSF STC-1 
concentration; APOE 4 carriers had increased concentrations of CSF STC-1 
compared with non-carriers (mean, 280 pg/mL, SD (76), vs. mean 240 pg/mL, 
SD (73), P=0.048).  
 
 
DISCUSSION 
 
The biological function of STC-1 as a key regulator of neuronal calcium 
homeostasis16, the potential association of dysregulated calcium homeostasis 
with neurodegenerative diseases,17,18 and the increased STC-1 expression in 
cerebrovascular disease13,19 led us to hypothesize that the STC-1 concentration in 
CSF could be altered in AD and/or other neurodegenerative diseases. We found 
that: 1) STC-1 was readily measureable in CSF using a well established ELISA, 
2) CSF STC-1 concentration was significantly increased in neurochemically 
verified AD cohort compared to CNC, 3) there was no significant difference in 
the levels of STC-1 and CNC in a well-characterized AD cohort, however, the 
levels of STC-1 was higher in mAD and sMCI patients, 4) patients with other 
dementias had significantly lower levels of CSF STC-1 compared with AD 
dementia, prodromal AD and CNC groups, and 5) the levels of STC-1 were 
significantly higher in APOE-carrier than non-carriers.  
 
In our exploratory cohort of neurochemically verified AD patients, the levels of 
STC-1 was significantly increased in AD vs. CNC. However, in cohort B, there 
was no significant difference in the levels of STC-1 between AD patients and 
prodromal AD, and in cohort C, the levels of STC-1 were lower in AD patients 
compared with CNC. At present, we do not have any definite explanation to why 
STC-1 was increased in neurochemically verified AD patients as compared to 
non-AD cases in cohort A, and not in the other two cohorts. However, one may 
speculate that the increase could be due to bias in selectivity as the diagnosis of 
AD was based on the results of the core AD biomarker cut-offs in this cohort 
with no clinical data (other than that the patients sought medical advice at a 
memory clinic) available. Further, the non-AD subjects in cohort A may suffer 
from other dementias that in the other cohorts tended to be associated with lower 
CSF STC-1 concentration. A replicable finding from both cohort B and C was 
that the levels of STC-1 were significantly lower in patients with DLB and VaD 
compared to CNC and AD. The mechanism of why the level of STC-1 is reduced 
in DLB and VaD is not fully understood. In the latter, one could speculate, based 
on the results from the previous experimental studies of STC-1 that cerebral or 
vascular ischemia may result in higher tissue uptake of STC-1, thereby, reduced 
levels in CSF.13,20 In addition, the levels of STC-1 were significantly increased in 
APOE 4 carriers vs. non-carriers. Also, these findings were not consistent across 
the cohorts; the reason for the lack of consistency is at present unknown. 
 
In summary, our study provides no clear support for CSF STC-1 as a biomarker 
for AD. This conclusion is supported by the lack of robust association of CSF 
STC-1 with established CSF AD biomarkers. However, one replicable result was 
the low CSF STC-1 concentration seen in the heterogeneous group of dementias 
other than AD. DLB and VaD stand out as the specific other dementia diagnosis 
with the lowest CSF STC-1 concentrations. Further research is warranted to 
examine this in closer detail and, if verified, clarify the causal relationships.  
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Figure legends/Tables 
 
 
 
 
 
Table 1. Demographic characteristics of the study population 
Characteristics CNC sMCI pAD OD mAD AD 
Cohort A, n 20 NA NA NA NA 20 
    Age at LP, mean (SD), y 69 (5) NA NA NA NA 71 (8.0) 
    Sex, F:M (%F) 11 (55) NA NA NA NA 12 (60) 
    Aβ1-42, pg/mL 810 (149) NA NA NA NA 467 (95) 
    P-tau, pg/mL 39 (8) NA NA NA NA 112 (25) 
    T-tau, pg/mL 252 (60) NA  NA NA 972 (302) 
Cohort B, n NA NA 12 19 NA 12 
   Age at LP, mean (SD), y NA NA 76 (4) 72 (9) NA 75 (8) 
   Gender F:M (%F) NA NA 4 (33) 13 (56) NA 8 (73%) 
   MMSE (range 0-30)  NA NA 25 (2) 22.1 (6.0) NA 21 (5.) 
   Aβ1-42, pg/mL NA NA 537 (342) 610 (217) NA 480 (210) 
   P-tau, pg/mL NA NA 79 (45) 50 (24) NA 94 (53) 
   T-tau, pg/mL NA NA 524 (296) 307 (175) NA 621 (327) 
Cohort C, n 20 13 6 15 8 18 
   Age at LP, mean (SD), y 74 (5) 71 (4) 73 (4) 74 (4) 76 (3) 73 (4) 
   Gender F:M (%F) 10 (50) 8 (61) 3 (50) 5 (33) 4 (50) 10 (55) 
   MMSE (range 0-30), 28 (2) 28 (1) 27 (2) 22 (6) 21 (3) 21 (4) 
   APOE ε4, +: −, no. (% +) 4 (20) 5 (38) 1 (16) 7 (47) 3 (37) 5 (27) 
   Aβ1-42, pg/mL 895 (233) 696 (216) 437 (90) 591 (313) 472 (131) 397 (114) 
   P-tau, pg/mL 65 (21) 59 (23) 94 (14) 306 (89) 91 (44) 109 (32) 
   T-tau, pg/mL 311 (90) 308 (109) 492 (70) 50 (16) 500 (217) 697 (245) 
All the values are presented as mean (SD). 
Abbreviations: AD, Alzheimer’s disease; MCI, cognitive mild impairment; CNC, cognitively normal 
controls; sMCI, stable MCI; mAD, mixed AD; pAD, prodromal AD; OD, other dementia than AD; LP, 
lumbar puncture; MMSE, mini mental state examination; APOE, apolipoprotein E; BMI, body mass index, 
CSF, cerebrospinal fluid; NA, not available. 
APOE ε4+ genotype was defined by the presence of at least one APOE ε4 allele. 
 
Figure 1. CSF Stanniocalcin-1 concentrations in different diagnostic groups 
 
Stanniocalcin-1 (STC-1) was significantly elevated in neurochemically verified 
AD vs. controls (A). In cohort B, STC-1 was increased in AD patients compared 
to the prodromal AD and other dementias, however the increase was not 
significant when corrected for multiple group comparisons (B). In cohort C, the 
STC-1 was significantly lower in other dementias vs. sMCI and CNC (C). When 
all the three cohorts were combined, STC-1 differed significantly between other 
dementias and AD (D). Abbreviations: AD, Alzheimer’s disease; CNC, 
cognitively normal individuals; mAD, mixed AD; pAD, prodromal AD; OD, 
other dementias; sMCI, stable mild cognitive impairment. 
Figure 2. CSF Stanniocalcin-1 levels were lower in non-AD dementias.  
 
(A) Patients with AD had increased levels of STC-1 than patients with FTD, 
NAAD and UCD, however, the increase was not statistically significant when 
corrected for multiple group comparison. (B) The levels of STC-1 were lower in 
patients with DLB and VaD. Abbreviations: AD, Alzheimer’s disease; pAD, 
prodromal AD; FTD, frontotemproal dementia; NAAD, Non-AD dementia; 
UCD, unclear cognitive decline; mAD, mixed AD, sMCI, stable MCI, CNC, 
cognitively normal controls; DLB, dementia with Lewy bodies; VaD, vascular 
dementia. 
 
Figure 3. Correlation with core AD biomarkers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Stanniocalcin levels and MMSE 
scores
 In cohort B, Stannioclacin-1 (STC-1) levels did not correlate with mini-mental 
state examination (MMSE) scores, while there was a significant correlation 
between STC-1 and MMSE score in cohort C. 
 
 
